newsfilter
← Latest News
PR Newswire·

Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million;